Genetron Holdings Limited

22.77+2.25+10.96%Vol 687.27K1Y Perf 43.53%
Apr 9th, 2021 16:00 DELAYED
BID21.92 ASK22.94
Open20.50 Previous Close20.52
Pre-Market- After-Market-
 - -  - -%
Target Price
19.50 
Analyst Rating
— — 0.00
Potential %
-14.36 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★     51.11
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap2.01B 
Earnings Rating
Price Range Ratio 52W %
61.04 
Earnings Date
25th Mar 2021

Today's Price Range

20.3123.38

52W Range

9.0331.54

Summary:

Neutral

Technical Indicators: Sell
Moving Averages: Strong Buy
Performance
1 Week
0.13%
1 Month
0.35%
3 Months
38.84%
6 Months
97.83%
1 Year
43.53%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
GTH22.772.250010.96
AAPL132.992.63002.02
GOOG2 285.8820.44000.90
MSFT255.852.60001.03
XOM55.87-0.1300-0.23
WFC40.500.47001.17
JNJ161.25-1.7200-1.06
FB312.46-0.5600-0.18
GE13.600.15001.12
JPM156.281.16000.75
Earnings HistoryEstimateReportedSurprise %
Q03 2020--0.08-
Q02 2020--0.23-
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume687.27K
Shares Outstanding88.36M
Trades Count6.39K
Dollar Volume22.28M
Avg. Volume432.14K
Avg. Weekly Volume403.59K
Avg. Monthly Volume324.03K
Avg. Quarterly Volume409.38K

Genetron Holdings Limited (NASDAQ: GTH) stock closed at 22.77 per share at the end of the most recent trading day (a 10.96% change compared to the prior day closing price) with a volume of 687.53K shares and market capitalization of 2.01B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 697 people. Genetron Holdings Limited CEO is Sizhen Wang.

The one-year performance of Genetron Holdings Limited stock is 43.53%, while year-to-date (YTD) performance is 62.64%. GTH stock has a five-year performance of %. Its 52-week range is between 9.03 and 31.54, which gives GTH stock a 52-week price range ratio of 61.04%

Genetron Holdings Limited currently has a PE ratio of -1.70, a price-to-book (PB) ratio of 7.36, a price-to-sale (PS) ratio of 37.12, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -244.75%, a ROC of -1 254.61% and a ROE of -25 381.40%. The company’s profit margin is -%, its EBITDA margin is -792.50%, and its revenue ttm is $54.13 Million , which makes it $0.61 revenue per share.

Of the last four earnings reports from Genetron Holdings Limited, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Genetron Holdings Limited’s next earnings report date is -.

The consensus rating of Wall Street analysts for Genetron Holdings Limited is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Genetron Holdings Limited stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Genetron Holdings Limited has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Genetron Holdings Limited has a Neutral technical analysis rating based on Technical Indicators (ADX : 24.05, ATR14 : 2.36, CCI20 : -142.00, Chaikin Money Flow : -0.25, MACD : -0.54, Money Flow Index : 37.36, ROC : -19.62, RSI : 40.51, STOCH (14,3) : 21.65, STOCH RSI : 0.23, UO : 37.34, Williams %R : -78.35), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Genetron Holdings Limited in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

Genetron Holdings Limited

Genetron Holdings Ltd is an oncology company in China. It is specialized in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The company generates revenue through precision oncology testing and development services. Precision oncology testing includes the diagnosis and monitoring and early screening performed in the form of LDT services and IVD products. Development services consist of research services and sequencing services.

CEO: Sizhen Wang

Telephone: +86 1050907500

Address: No.8 Life Science Parkway, Beijing 102206, , CN

Number of employees: 697

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

57%43%

Bearish Bullish

59%41%

Bearish Bullish

64%36%

News

Stocktwits